Controls were not ascertained specifically for neurological disorders, but all were obtained from adult samples providing informed consent so developmental disorders should be exceedingly rare. Of individuals with known ethnicity, 81.2% are Caucasian (primarily European descent), 2% are African/African American, and 16.5% are other/mixed ancestry. Due to the slight enrichment of African-American cases compared to our control samples, we modeled the potential impact of large CNV stratification and found no evidence for an overall enrichment of unique large CNVs in the African cohort (Supplemental Figure 10). DNA was obtained from cell lines and blood-derived samples generated for association studies of various phenotypes. Datasets are detailed in Supplemental Table 4. Data were obtained from the following sources: HGDP16,53; NINDS (dbGaP accession no. phs00008916,54; PARC/PARC2)55,56; London (parents of asthmatic children)15; FHCRC (pre-release data provided courtesy of Aaron Aragaki, Charles Kooperberg, and Rebecca Jackson as part of an ongoing genome-wide association study to identify genetic components of hip fracture in the Women's Health Initiative); InCHIANTI (data provided by InCHIANTI study of aging; http://www.inchiantistudy.net15,57); and WTCCC2 (NBS)58. Control CNV arrays were analyzed as described
